MannKind Corporation (NASDAQ:MNKD) persists its position slightly strong in context of buying side, while shares price plunged -4.11% during latest trading session. MannKind Corp. (MNKD) has initiated new marketing strategies to accelerate disappointing sales of its Afrezza inhalation powder. Despite early hype, the inhalable insulin has failed to gain traction since its launch in 2014.
In a bid to revive sales, MannKind launched a new titration pack which contains 60 four-unit cartridges, 60 eight-unit cartridges and 60 twelve-unit cartridges of Afrezza. The new packs are aimed at reducing costs for patients and simplifying prescriptions for physicians, who will now have more choices of dose quantity. Afrezza was authorized in June 2014 by the Food and Drug Administration (FDA) and was projected to generate annual sales of $600 million. Unfortunately, Afrezza drug sales never lived up to expectations, and MannKind managed to ship only $17 million worth of product during the first 9 months, which pocketed only $5 million from the deal.
Narrow down focus to other ratios, the co has current ratio of 0.50 that indicates if MNKD lies in 1.3% to 3% then it is acceptable for both active and passive investors, but sometimes its varies industry to industry. Generally, it indicates good short-term financial strength. Street is more conscious on this after SunEdison, Inc. case. To make strengthen these views, the active industry firm has Quick Ratio of 0.40, which indicates firm has sufficient short-term assets to cover its immediate liabilities.
Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) also run on active notice, stock price ascend 4.61% after traded at $2.27 in most recent trading session. EBIO price to current year EPS stands at 25.60%. Moving toward ratio analysis, it has current ratio of 5.10 and quick ratio was calculated as 5.10. The debt to equity ratio appeared as 0.01 for seeing its liquidity position.
Taking notice on volatility measures, price volatility of stock was 6.47% for a week and 7.22% for a month. The price volatility’s Average True Range for 14 days was 0.15. On these bases, analysts would recommend this stock as an “Active Revolving Stocks.” The firm attains analyst recommendation of 2.00 out of 1-5 scale with week’s performance of 4.13%. EBIO’s institutional ownership was registered as 40.70%, while insider ownership was 3.40%.